NFKB1 and hepatocellular carcinoma: In a previous study, we showed how the introduction of a new lipophilic three-carbon chain in place of H-3α of OA can determine the inhibition of NF-κB activation in hepatocellular carcinoma (HCC) cell lines overexpressing this factor and characterized by innate drug resistance [16].